WO2004022590A3 - Immunogenic muc1 glycopeptides - Google Patents

Immunogenic muc1 glycopeptides Download PDF

Info

Publication number
WO2004022590A3
WO2004022590A3 PCT/EP2003/009882 EP0309882W WO2004022590A3 WO 2004022590 A3 WO2004022590 A3 WO 2004022590A3 EP 0309882 W EP0309882 W EP 0309882W WO 2004022590 A3 WO2004022590 A3 WO 2004022590A3
Authority
WO
WIPO (PCT)
Prior art keywords
muc1
peptides
producing
methods
apcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/009882
Other languages
French (fr)
Other versions
WO2004022590A2 (en
Inventor
Franz-Georg Hanisch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Center Cologne GmbH
Original Assignee
Cell Center Cologne GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10305607A external-priority patent/DE10305607A1/en
Application filed by Cell Center Cologne GmbH filed Critical Cell Center Cologne GmbH
Priority to EP03793810A priority Critical patent/EP1537143A2/en
Priority to US10/525,672 priority patent/US20060142546A1/en
Priority to AU2003258710A priority patent/AU2003258710A1/en
Publication of WO2004022590A2 publication Critical patent/WO2004022590A2/en
Publication of WO2004022590A3 publication Critical patent/WO2004022590A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided are novel MUC1 peptides for use in anti-tumor vaccination and methods of producing those peptides. Furthermore, methods of producing a population of autologous antigen presenting cells (APCs) and of producing genetically engineered APCs, which are capable of inducing effective immune responses against MUC1 are described. The described peptides are particularly useful for the treatment of breast cancer or other MUC1-positive carcinomas including colorectal, pancreatic and gastric carcinomas.
PCT/EP2003/009882 2002-09-05 2003-09-05 Immunogenic muc1 glycopeptides Ceased WO2004022590A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03793810A EP1537143A2 (en) 2002-09-05 2003-09-05 Immunogenic muc1 glycopeptides
US10/525,672 US20060142546A1 (en) 2002-09-05 2003-09-05 Immunogenic muc1 glycopeptides
AU2003258710A AU2003258710A1 (en) 2002-09-05 2003-09-05 Immunogenic muc1 glycopeptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10241207.3 2002-09-05
DE10241207 2002-09-05
DE10305607A DE10305607A1 (en) 2002-09-05 2003-02-11 Immunogenic MUC1 glycopeptides
DE10305607.6 2003-02-11

Publications (2)

Publication Number Publication Date
WO2004022590A2 WO2004022590A2 (en) 2004-03-18
WO2004022590A3 true WO2004022590A3 (en) 2005-01-20

Family

ID=31979471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/009882 Ceased WO2004022590A2 (en) 2002-09-05 2003-09-05 Immunogenic muc1 glycopeptides

Country Status (4)

Country Link
US (1) US20060142546A1 (en)
EP (1) EP1537143A2 (en)
AU (1) AU2003258710A1 (en)
WO (1) WO2004022590A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030840A1 (en) * 2004-09-14 2006-03-23 National Institute Of Advanced Industrial Scienceand Technology Process for synthesis of mucin-type peptides and muc1-related glycopeptides
ES2720288T3 (en) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferation of cells expressing MUC1
EP2526957A3 (en) * 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
GB2437727B (en) * 2006-05-04 2011-04-20 Univ Open Aptamers directed to MUC1
AU2007304590A1 (en) 2006-10-04 2008-04-10 Cancer Research Technology Limited Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
KR100995340B1 (en) * 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 Vaccine containing monocyte or undifferentiated myeloid cells loaded with ligand and antigen of natural killer T cells
WO2009108807A1 (en) * 2008-02-26 2009-09-03 The Regents Of The University Of California Glycopeptides and methods of making and using them
CN102272290B (en) 2008-10-09 2018-08-14 米纳瓦生物技术公司 Method for inducing pluripotency in a cell
MX2011013385A (en) 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Methods for culturing stem and progenitor cells.
EP2560989B1 (en) 2010-04-19 2017-03-22 Sumitomo Bakelite Co., Ltd. Cancer-related glycopeptide epitopes, antibodies and methods of use
CA2800911A1 (en) * 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp PROCESS FOR OBTAINING PLURIPOTENT STEM CELLS
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
CN119367549A (en) 2017-06-21 2025-01-28 芬兰吉利科斯有限公司 Hydrophilic linkers and conjugates thereof
IL272810B2 (en) 2017-08-21 2025-10-01 Savicell Diagnostic Ltd Methods of diagnosing and treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050527A1 (en) * 1997-05-08 1998-11-12 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050527A1 (en) * 1997-05-08 1998-11-12 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
APOSTOLOPOULOS V ET AL: "MUC1 PEPTIDE EPITOPES ASSOCIATED WITH FIVE DIFFERENT H-2 CLAS I MOLECULES", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 27, 1997, pages 2579 - 2587, XP001009768, ISSN: 0014-2980 *
GELDHOF P ET AL: "Proteinases released in vitro by the parasitic stages of the bovine abomasal nematode Ostertagia ostertagi", PARASITOLOGY, vol. 121, no. 6, December 2000 (2000-12-01), pages 639 - 647, XP009035151, ISSN: 0031-1820 *
HANISCH FRANZ-GEORG ET AL: "O-linked glycans control glycoprotein processing by antigen-presenting cells: A biochemical approach to the molecular aspects of MUC1 processing by dendritic cells.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 33, no. 12, December 2003 (2003-12-01), pages 3242 - 3254, XP009035167, ISSN: 0014-2980 *
PIETERSZ G A ET AL: "Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 19, April 2000 (2000-04-01), pages 2059 - 2071, XP004202504, ISSN: 0264-410X *

Also Published As

Publication number Publication date
AU2003258710A1 (en) 2004-03-29
WO2004022590A2 (en) 2004-03-18
US20060142546A1 (en) 2006-06-29
EP1537143A2 (en) 2005-06-08

Similar Documents

Publication Publication Date Title
WO2004022590A3 (en) Immunogenic muc1 glycopeptides
AU2003256912A1 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO1998016238A3 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
IL102687A (en) Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DK1104306T3 (en) Preparations of CpG and Saponin Adjuvants and Methods for Using Them
AU5898400A (en) Hla binding peptides and their uses
AUPM322393A0 (en) Mucin carbohydrate compounds and their use in immunotherapy
AU4673099A (en) Use of bioadhesives and adjuvants for the mucosal delivery of antigens
PL1760088T3 (en) Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
HUP0401753A3 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
AU2002338832A1 (en) Vaccine
AU5214200A (en) Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
ATE389712T1 (en) CANCER IMMUNOTHERAPY WITH SEMI-ALLOGENE CELLS
DK1267924T3 (en) Immunotherapeutic methods and compositions
WO1998058956A3 (en) Methods for inducing an immune response involving prime-boost protocols
ES2177927T3 (en) COMPOSITION TO CAUSE AN IMMUNOLOGICAL REACTION TO A NON-PROTEIN ANTIGEN DETERMINANT
AU2003242535A1 (en) Improved polysaccharide and glycoconjugate vaccines
WO2004006861A3 (en) Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease
DE69232395D1 (en) ANTI-TUMOR VACCINE
WO2003033520A3 (en) Anticancer vaccine and diganostic methods and reagents
WO2004031230A3 (en) Novel mhc ii associated peptides
WO2005019435A8 (en) Anti-cancer vaccines
UY26266A1 (en) ANTIGEN ASSOCIATED WITH TUMORS (R11) LAW 17164
WO2000012122A3 (en) Low-molecular fragments of hyaluronic acid for the preparation of vaccines
WO2003093298A3 (en) Immunogenic peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003258710

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003793810

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003793810

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006142546

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10525672

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10525672

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP